Cargando…

Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine

The implementation of nanomedicine in cellular, preclinical, and clinical studies has led to exciting advances ranging from fundamental to translational, particularly in the field of cancer. Many of the current barriers in cancer treatment are being successfully addressed using nanotechnology-modifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Dean, Wang, Chung-Huei Katherine, Chow, Edward Kai-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643796/
https://www.ncbi.nlm.nih.gov/pubmed/26601235
http://dx.doi.org/10.1126/sciadv.1500439
_version_ 1782400568019386368
author Ho, Dean
Wang, Chung-Huei Katherine
Chow, Edward Kai-Hua
author_facet Ho, Dean
Wang, Chung-Huei Katherine
Chow, Edward Kai-Hua
author_sort Ho, Dean
collection PubMed
description The implementation of nanomedicine in cellular, preclinical, and clinical studies has led to exciting advances ranging from fundamental to translational, particularly in the field of cancer. Many of the current barriers in cancer treatment are being successfully addressed using nanotechnology-modified compounds. These barriers include drug resistance leading to suboptimal intratumoral retention, poor circulation times resulting in decreased efficacy, and off-target toxicity, among others. The first clinical nanomedicine advances to overcome these issues were based on monotherapy, where small-molecule and nucleic acid delivery demonstrated substantial improvements over unmodified drug administration. Recent preclinical studies have shown that combination nanotherapies, composed of either multiple classes of nanomaterials or a single nanoplatform functionalized with several therapeutic agents, can image and treat tumors with improved efficacy over single-compound delivery. Among the many promising nanomaterials that are being developed, nanodiamonds have received increasing attention because of the unique chemical-mechanical properties on their faceted surfaces. More recently, nanodiamond-based drug delivery has been included in the rational and systematic design of optimal therapeutic combinations using an implicitly de-risked drug development platform technology, termed Phenotypic Personalized Medicine–Drug Development (PPM-DD). The application of PPM-DD to rapidly identify globally optimized drug combinations successfully addressed a pervasive challenge confronting all aspects of drug development, both nano and non-nano. This review will examine various nanomaterials and the use of PPM-DD to optimize the efficacy and safety of current and future cancer treatment. How this platform can accelerate combinatorial nanomedicine and the broader pharmaceutical industry toward unprecedented clinical impact will also be discussed.
format Online
Article
Text
id pubmed-4643796
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-46437962015-11-23 Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine Ho, Dean Wang, Chung-Huei Katherine Chow, Edward Kai-Hua Sci Adv Reviews The implementation of nanomedicine in cellular, preclinical, and clinical studies has led to exciting advances ranging from fundamental to translational, particularly in the field of cancer. Many of the current barriers in cancer treatment are being successfully addressed using nanotechnology-modified compounds. These barriers include drug resistance leading to suboptimal intratumoral retention, poor circulation times resulting in decreased efficacy, and off-target toxicity, among others. The first clinical nanomedicine advances to overcome these issues were based on monotherapy, where small-molecule and nucleic acid delivery demonstrated substantial improvements over unmodified drug administration. Recent preclinical studies have shown that combination nanotherapies, composed of either multiple classes of nanomaterials or a single nanoplatform functionalized with several therapeutic agents, can image and treat tumors with improved efficacy over single-compound delivery. Among the many promising nanomaterials that are being developed, nanodiamonds have received increasing attention because of the unique chemical-mechanical properties on their faceted surfaces. More recently, nanodiamond-based drug delivery has been included in the rational and systematic design of optimal therapeutic combinations using an implicitly de-risked drug development platform technology, termed Phenotypic Personalized Medicine–Drug Development (PPM-DD). The application of PPM-DD to rapidly identify globally optimized drug combinations successfully addressed a pervasive challenge confronting all aspects of drug development, both nano and non-nano. This review will examine various nanomaterials and the use of PPM-DD to optimize the efficacy and safety of current and future cancer treatment. How this platform can accelerate combinatorial nanomedicine and the broader pharmaceutical industry toward unprecedented clinical impact will also be discussed. American Association for the Advancement of Science 2015-08-21 /pmc/articles/PMC4643796/ /pubmed/26601235 http://dx.doi.org/10.1126/sciadv.1500439 Text en Copyright © 2015, The Authors http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (http://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Reviews
Ho, Dean
Wang, Chung-Huei Katherine
Chow, Edward Kai-Hua
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
title Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
title_full Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
title_fullStr Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
title_full_unstemmed Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
title_short Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
title_sort nanodiamonds: the intersection of nanotechnology, drug development, and personalized medicine
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643796/
https://www.ncbi.nlm.nih.gov/pubmed/26601235
http://dx.doi.org/10.1126/sciadv.1500439
work_keys_str_mv AT hodean nanodiamondstheintersectionofnanotechnologydrugdevelopmentandpersonalizedmedicine
AT wangchunghueikatherine nanodiamondstheintersectionofnanotechnologydrugdevelopmentandpersonalizedmedicine
AT chowedwardkaihua nanodiamondstheintersectionofnanotechnologydrugdevelopmentandpersonalizedmedicine